Project Grant R21AG095557
Award Date 12/15/25
Completion Date 11/30/27
Dollars Obligated $429K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbia, MO 65211, USA
Similar Awards
- This $437,375 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to investigate the role of the protein NEK7 in suppressing inflammation in the aging heart. The primary research objectives are to: Determine if NEK7 activity decreases with age in mouse cardiomyocytes and whether increasing NEK7 activity can mitigate age-related cardiac inflammation and remodeling. Assess the potential cardioprotective effects of boosting NEK7 activity in...
- This Cooperative Agreement award, provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866), aims to discover and validate novel antifibrotic compounds for treating cardiac fibrosis in aging populations. The $900,195 award, effective from September 1, 2025 to August 31, 2027, will leverage cutting-edge technologies such as human induced pluripotent stem cells (iPSCs), artificial intelligence (AI), and advanced preclinical models. The project...
- This $485,375 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research at the University of Washington to investigate genomic alterations in skeletal muscle associated with aging. The key objectives are to: Explore if alternative splicing of mRNA results in quantitative differential isoform changes associated with aging, potentially leading to increased expression of non-functional proteins relevant for healthy muscle function. The researchers...
- This federal Project Grant award of $785,198.00 from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) will support research on the role of chaperone-mediated autophagy (CMA) in cardiac fibrosis and myocardial infarction repair. The primary objective is to study how CMA, a process that selectively removes specific proteins, regulates the phenotypic transitions of fibroblasts and myofibroblasts in the infarcted heart. The award will fund...
- The federal Project Grant award of $126,387 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The Johns Hopkins University to investigate the role of the translation factor eIF5A and its hypusination in the development of heart failure with preserved ejection fraction (HFpEF). The key research aims include: 1) Testing the hypothesis that reduced hypusination of eIF5A impairs the translation of ubiquitin precursors and...
- This $292,279 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports Artiam Bio Inc., a small disadvantaged biotechnology company in Cary, North Carolina, to validate the APT101 compound for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in an aging murine model. The project aims to assess the comparative efficacy of APT101, a selective agonist of the apelin receptor (APJ), in a clinically relevant...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The $708,266 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will fund a 4-year research project to determine the role of SALTE1 in vascular aging and HFPEF, and examine the underlying...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $639,740.00 to investigate the role of the CD38 enzyme in the development of chronic lung conditions following viral infections like COVID-19. The research aims to explore how targeting CD38 on CD8 tissue resident memory (TRM) cells could mitigate age-associated lung fibrosis after viral pneumonia. The award, effective December 15, 2024 through November 30, 2029, will support the lead researcher...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) in the amount of $699,133 supports research to investigate the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The key objectives are to: 1) measure transcription, chromatin accessibility and histone modifications in heart, kidney and liver tissues to map the regulatory landscape during HFPEF development in a rat model;...
- This $651,009 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of the structural protein junctophilin-2 (JP2) in regulating calcium signaling within cardiac fibroblasts and its impact on cardiac fibrotic remodeling following injury. The research, conducted by the University of Iowa from September 2025 through May 2029, employs advanced molecular, physiological, and biochemical techniques,...